First MHRA-approved low-dose atropine eye drop to slow the progression of myopia (short-sightedness) in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.

McConnell’s hemp ban risks wiping out most U.S. hemp-derived products, while MSOs pin hopes on Schedule III rescheduling that ...

From cutting-edge vision correction (including LASIK) to next-generation cataract surgery, here’s your insider guide to ...

Trump’s GLP-1 price deal slashes costs and expands selective Medicare coverage—threatening telehealth startups and sparking a ...

Bausch + Lomb Corporation , a leading global eye health company dedicated to helping people see better to live better, will outline the next chapter of its evolution today during an investor day event ...